Identification and Management of Immune-Related Adverse Events in the Emergency Setting: Module 12 of 12


It is important to note there are twelve ACI online modules, you are currently reviewing module twelve. You may complete any of the modules in the order you choose. Each module can be completed independently for continuing education credit. 

The Identification and Management of Immune-Related Adverse Events in the Emergency Department module covers how irAEs differ from the side effects associated with chemotherapy, patient assessment, and emergent management of irAEs. The module also includes case studies on irAE management in the Emergency Department.

Module 12
Ronny Mario Otero MD, FAAEM – University of Michigan

Educational Objectives

  • Discuss commonly used medications such as corticosteroids and mycophenolate
  • Differentiate between side effects associated with chemotherapy and irAEs (including mechanisms and timing)
  • Recognize common signs and symptoms and patient histories indicative of irAEs during an assessment
  • Illustrate how to execute emergent management of irAEs (including communications with cancer team, patient education, treatment for low grade to severe events)

Target Audience

The ACI 2017 video series have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

Related Class Content

All modules offer Continuing Education (CE) Credit

Register/Access Class

Target Audience
Clinician Icon

Credit Available
Oct. 6, 2017- Sept. 30, 2018

  • CME: 0.5 AMA PRA Category 1 Credit(s)™
  • CNE: 0.5 contact hours, with 0.2 pharmacotherapy contact hours
  • CPE: 0.5 contact hours (0.05 CEUs)

Approximate Time to Complete
0.5 hours


Please use one of the following Internet browsers to open this activity: Chrome, Firefox, or Safari browsers in order to view this online activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer 

The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from 
Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.